Grand Pharmaceutical Group
Tracked across 5 events · 30 articles · First seen Apr 09, 2026 · Last active Jul 23, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Regulatory
Impact: Grand Pharmaceutical Group, a Chinese company, achieved a rare win in Washington as CFIUS rejected FastWave's request for a national security review of its investment. This allows Grand Pharmaceutical Group to maintain its 40% stake in FastWave.
Apr 09, 2026 · 6 articles
Tech
Impact: GSK plc licensed the Mo-rez drug from Grand Pharmaceutical Group in 2023, indicating a potential future revenue stream for Grand Pharmaceutical Group.
Apr 12, 2026 · 6 articles
Tech
Impact: Grand Pharmaceutical Group is an investor in Xeltis, and the successful clinical data for aXess™ could enhance the value of their investment.
Apr 21, 2026 · 6 articles
Business
Impact: Renfu, a condom company selling in China, did not immediately respond to a request for comment regarding the price increases.
Apr 23, 2026 · 6 articles
Regulatory
Impact: Grand Pharmaceutical Group's positive phase III data for Ris-Rez was mentioned as part of GSK's broader oncology pipeline.
Jul 22, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Grand Pharmaceutical Group live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard